ICENI GLYCOSCIENCE LIMITED

Their core work

Iceni Glycoscience is a UK-based SME specializing in glycoscience — the study and manipulation of sugar molecules (glycans) that play critical roles in biological recognition, immune response, and disease. They provide expertise in enzymatic synthesis of glycan structures and glycomimetics, contributing to training networks that develop the next generation of glycoscientists. Their work spans from understanding how sugars mediate immune signaling (the Siglec-glycan axis) to developing synthetic sugar-based compounds with pharmaceutical potential.

What they specialise in

How they've shifted over time

Iceni's earliest H2020 involvement (PoLiMeR, 2018) was oriented toward systems medicine and metabolic modeling — glycogen and lipid metabolism in liver disease, using tools like genome-scale models and organ-on-chip. From 2019 onward, the focus shifted decisively toward applied glycoscience: chemical biology, glycomimetic design, immune modulation through sugar-based molecules, and microbiome interactions. The trajectory shows a move from understanding glycan biology in disease contexts toward actively engineering glycan-based compounds with therapeutic potential.

Iceni is moving toward the pharmacologically actionable side of glycoscience — designing synthetic sugar analogues that modulate immune responses — making them increasingly relevant for drug discovery collaborations.

How they like to work

Iceni has participated exclusively as a partner in MSCA training networks, never as coordinator. With 37 unique consortium partners across 14 countries from just 3 projects, they operate in large, distributed academic-industrial training consortia typical of MSCA-ITN schemes. This suggests they are valued as an industry training host bringing specialized commercial glycoscience expertise that academic partners lack.

Despite only 3 projects, Iceni has built a broad European network of 37 partners across 14 countries, reflecting the large consortium sizes typical of MSCA-ITN programs. Their reach spans most of the EU, with no single geographic cluster dominating.

What sets them apart

Iceni occupies a rare niche as a private SME with deep glycoscience expertise — a field dominated almost entirely by academic labs. This makes them a valuable industry partner for training networks that need to expose early-career researchers to commercial glycan applications. For consortium builders, they offer something hard to find elsewhere: a company that can bridge academic glycobiology research and real-world product development in carbohydrate chemistry.

Highlights from their portfolio

• GLYTUNES
  Most recent project (2021-2025) targeting the Siglec-glycan immune axis with glycomimetics — represents the company's clearest move toward drug-discovery-relevant glycoscience.
• SWEET CROSSTALK
  Interdisciplinary glycoscience training network bridging microbiome research with chemical biology, connecting two high-growth fields through glycan chemistry.
• PoLiMeR
  Earliest project showing Iceni's range beyond pure carbohydrate chemistry into systems medicine, metabolic modeling, and organ-on-chip technologies.